20Apr
19Apr
Pyramid Biosciences and GeneQuantum Healthcare Announce Preclinical Data for GQ1010, a Potential Best-In-Class TROP2-Targeted Antibody Drug Conjugate, at the 2023 AACR Annual Meeting
Pyramid Biosciences, Inc., a privately-held, clinical-stage biotechnology company focused on developing transformative medicines for patients with cancer, and its partner GeneQuantum Healthcare (Suzhou) Co. Ltd, a privately-held biotechnology company based in China, announced data at the American Association for Cancer Research (AACR) Annual Meeting 2023 highlighting the preclinical efficacy and safety profile of GQ1010, a potential best-in-class antibody drug conjugate (ADC) targeting trophoblast cell surface antigen 2 (TROP2), across several in vitro and in vivo models. The poster presentation highlights...
14Apr
Pyramid Biosciences Expands Oncology Pipeline with In-Licensing of GQ1010, a Potential Best-in-class TROP2 Targeted Antibody Drug Conjugate (ADC), from GeneQuantum Healthcare
Pyramid Biosciences, Inc., a privately-held, clinical-stage biotechnology company focused on developing transformative medicines for patients with cancer, today announced that it has entered into an exclusive license agreement with GeneQuantum Healthcare (Suzhou) Co. Ltd, a privately-held biotechnology company based in China, to develop and commercialize GQ1010, a potential best-in-class antibody drug conjugate (ADC) targeting TROP2, worldwide except for Greater China (mainland China, Hong Kong, Macau, and Taiwan). GQ1010 has shown a highly differentiated preclinical profile, and is anticipated to enter...
13Apr
DetraPel Announces the Re-Brand of its Industrial Pillar to Impermea Materials, an Advanced Materials Company Manufacturing PFAS-Free, Fluorine-Free and Plastic Alternative Solutions
Formally known as DetraPel, Impermea Materials unveils its new brand as it expands its offerings across food & packaging, textiles, automotive, and more as regulatory and consumer demands increase for PFAS-free and plastic-free goods. Read more >>
11Apr
Astrocyte Pharmaceuticals Announces Theodore Liston, Ph.D., Vice President of Research, as Recipient of the 2022 Innovation and Progress Award from the Journal Stroke
Astrocyte Pharmaceuticals Inc., a private drug discovery and development company advancing novel cerebroprotective therapeutics for patients with brain injuries, today announced that Theodore Liston, Ph.D., Vice President of Research at Astrocyte, received the 2022 Progress and Innovation Award from the journal Stroke for authoring one of the journal’s top three publications in 2022. The Innovation and Progress Award recognizes research that demonstrates “a new approach, new methodology, new interpretation of existing data, or new data with far-reaching implications.” Dr. Liston’s...
06Apr
Astrocyte Announces Initiation of an Extended Infusion Phase 1B Study of AST-004 for Stroke and Traumatic Brain Injuries
Astrocyte Pharmaceuticals Inc., a drug discovery and development company advancing novel cerebroprotective therapeutics for patients with brain injuries, is pleased to announce the initiation of a Phase 1B study of its lead candidate, AST-004, as an extended infusion in healthy volunteers. This adaptive-design clinical study will be conducted over the next four to six months at the QPS clinical research site in Groningen, Netherlands. AST-004 is a small molecule adenosine A3/A1 receptor agonist that has consistently shown promising cerebroprotective results...
06Apr
Clinical study shows Xylyx Bio’s Matrikynes® significantly improves the structure, function, and appearance of skin
Xylyx Bio, a regenerative medicine company developing breakthrough technologies for organ and tissue repair, today announced findings from an independent clinical study that validated that their proprietary Matrikynes® ingredient is safe and highly effective for anti-aging and other topical skin applications. Results from the study are reported in the white paper "Clinical evaluation of Matrikynes®: a novel cosmetic ingredient comprised of matrikine peptides". Developed through biomedical research aimed at better understanding and promoting tissue repair and wound healing, Matrikynes® is...
05Apr
Aras Innovator Enables OnWatch Scout, an Award-winning Advanced Monitoring Solution at MacGregor
Aras, which provides the most powerful low-code platform with applications to design, build and operate complex products, today announced that MacGregor, a leader in sustainable maritime cargo and load handling, utilized Aras Innovator® to further develop its OnWatch Scout, a condition-based and predictive maintenance service. OnWatch Scout unites performance data from essential equipment aboard a ship and provides real-time condition and predictive monitoring information to the crew. OnWatch Scout was developed by MacGregor as a step in the company's digital...
05Apr
Two Babson Ventures Named Startups to Watch by BostInno
BostInno recently named two ventures founded by Babson alumni—High Time Foods and DetraPel—as startups to watch for 2023. In all, BostInno spotlighted 23 Boston companies. “All of the companies BostInno highlighted this year have different goals, products, and team cultures,” the Boston-based business publication wrote, “but the common thread is that they are on the verge of breaking out.” Co-founded by Aakash Shah MBA’22 and Damian Felchlin MBA’21, High Time Foods is a provider of shelf-stable, plant-based meat. David Zamarin...
04Apr